Puma Biotechnology, Inc.
PBYI
Rank in Stocks
#13476
Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global... Puma Biotechnology, Inc. is a biopharmaceutical company dedicated to the global development and commercialization of treatments aimed at advancing cancer care. Its lead drug candidate, orally administered neratinib (PB272), targets a range of indications. These include patients with early-stage HER2-overexpressed/amplified breast cancer, as well as adults suffering from advanced or metastatic HER2-positive breast cancer when used in combination with capecitabine. Furthermore, PB272 is being explored for solid tumors exhibiting HER2 mutations. The company holds a licensing agreement with Pfizer, Inc. for this drug and has established sub-licensing partnerships with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Established in 2010, Puma Biotechnology maintains its headquarters in Los Angeles, California.
Share Price
$7.05
Last synced: 2026-11-20
Market Cap
$363.80M
Change (1 day)
-0.98%
Change (1 year)
44.17%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Puma Biotechnology, Inc. (PBYI)
Category
Healthcare
Operating Margin for Puma Biotechnology, Inc. (PBYI)
Operating Margin as of November 2026 TTM: 11.27%
According to Puma Biotechnology, Inc.'s latest financial reports, its current operating margin (TTM) is 11.27%. At the end of 2025 the company had an operating margin of 16.33%.
Operating Margin history for Puma Biotechnology, Inc. from 2007 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 11.27% | -30.99% |
| 2025 | 16.33% | 21.50% |
| 2024 | 13.44% | -2.96% |
| 2023 | 13.85% | 33.17% |
| 2022 | 10.40% | 1,939.22% |
| 2021 | 0.51% | -103.77% |
| 2020 | -13.51% | -51.35% |
| 2019 | -27.77% | -26.40% |
| 2018 | -37.73% | -96.43% |
| 2017 | -1,055.60% | 0.00% |
| 2016 | 0.00% | 0.00% |
| 2015 | 0.00% | 0.00% |
| 2014 | 0.00% | 0.00% |
| 2013 | 0.00% | 0.00% |
| 2012 | 0.00% | -100.00% |
| 2011 | 3,613.24% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 33.87% | -96.99% |
US
|
|
| -116.04% | -110.30% |
US
|
|
| 25.57% | -97.73% |
AU
|
|
| 31.23% | -97.23% |
BE
|
|
| 29.35% | -97.40% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Puma Biotechnology, Inc.'s operating margin
What is Puma Biotechnology, Inc.'s operating margin?
Puma Biotechnology, Inc.'s operating margin is 11.27%, as of Nov 2026.
What was Puma Biotechnology, Inc.'s operating margin in 2025?
In 2025, Puma Biotechnology, Inc.'s operating margin was 16.33%, compared with 13.44% in 2024.
How has Puma Biotechnology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Puma Biotechnology, Inc.'s operating margin was highest in 2025 (16.33%) and lowest in 2020 (-13.51%).
How does Puma Biotechnology, Inc.'s operating margin compare with similar companies?
Puma Biotechnology, Inc.'s operating margin (11.27%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 33.87%.